The Global Health Body Raises Alert Over Critical Scarcity of Obesity Jabs
Less than a tenth of individuals who could benefit from GLP-1 drugs like Wegovy have access to them, warns the WHO as it releases its first recommendations on the medications.
With more than one billion individuals worldwide currently obese, it is advocating for broader and more equitable access to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The latest guidelines recognises that obesity is a long-term condition that can be managed with holistic and ongoing support," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are significant barriers to universal access to the treatments that can aid individuals in losing considerable weight, notes the agency.
GLP-1 Therapy Shortage
Even in the current most optimistic scenario, the manufacturing of these medications might only reach approximately 100 million people – fewer than 10% of the global need, as stated by the WHO.
The recommendation calls on governments and firms to expand access, via strategies including voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.
The Way Obesity Jabs Work
These medications imitate a biological compound to slow digestion, reduce hunger and boost feelings of fullness so individuals consume fewer calories.
Patients typically see weight reduction after several weeks of starting on the weekly injections.
Research suggests patients may see weight return a year later of halting the treatment, because their usual hunger resume.
To be overweight or obese elevates your likelihood for experiencing medical conditions, like diabetes, heart disease, stroke, and some cancers.
Obesity affects people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, according to the WHO.
